<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01068873</url>
  </required_header>
  <id_info>
    <org_study_id>Temple IRB 12848</org_study_id>
    <nct_id>NCT01068873</nct_id>
  </id_info>
  <brief_title>Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)</brief_title>
  <acronym>KALMAR</acronym>
  <official_title>Kaletra and Maraviroc in Antiretroviral Therapy-Naïve Patients - KALMAR Study -Version 1.0 Amendment 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Temple University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this pilot study is to assess the efficacy of lopinavir/ritonavir&#xD;
      (Kaletra, a protease inhibitor, PI) when used in combination with maraviroc (Selzentry, an&#xD;
      HIV entry inhibitor) for the treatment of antiretroviral naïve HIV infected patients. Twenty&#xD;
      patients will be enrolled and studied for 48 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As patients with HIV are living longer it is important to explore antiretroviral treatments&#xD;
      which may reduce the development of long term complications while preserving future HIV&#xD;
      treatment options. This trial explores an antiretroviral treatment regimen which does not&#xD;
      include the nucleoside reverse transcriptase inhibitor class which is thought to have&#xD;
      long-term toxicity. This is a non-randomized, open label trial in participants meeting entry&#xD;
      requirements.&#xD;
&#xD;
      Participants will be evaluated at screening, baseline,and weeks 4, 8, 12, 24, 36, and 48 to&#xD;
      include clinical assessments as well as laboratory assessments.&#xD;
&#xD;
      An interim analysis will be performed when all patients have reached the week 24 visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor enrollment&#xD;
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess Proportion of Participants With HIV RNA Levels &lt;50 and &lt; 400 Copies/mL.</measure>
    <time_frame>week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HIV RNA &lt; 50 and &lt;400 Copies/ml.</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the Proportion of Participants at Study Termination With VL &lt; 50 Copies/ml.</measure>
    <time_frame>week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the Time to Viral Suppression (VL &lt; 50 Copies/ml).</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the Median Change in VL From Baseline to Week 24, to Week 48 and to Study Termination.</measure>
    <time_frame>week 24, week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the Changes in CD4+ T Cell Count.</measure>
    <time_frame>week 24, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Development of HIV Resistance Mutations and in HIV Co-receptor Tropism Changes in Participants Who Develop Virologic Rebound.</measure>
    <time_frame>week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>open label single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: lopinavir/ritonavir plus maraviroc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lopinavir/ritonavir plus maraviroc</intervention_name>
    <description>Lopinavir/ritonavir 400 mg/100 mg two tablets twice daily with Maraviroc 150 mg one tablet twice daily will be administered for 48 weeks to participants meeting entry criteria.</description>
    <arm_group_label>open label single arm</arm_group_label>
    <other_name>Lopinavir/ritonavir (Kaletra)</other_name>
    <other_name>Maraviroc (Selzentry)</other_name>
    <other_name>Nucleoside sparing regimen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient has signed and dated approved informed consent form.&#xD;
&#xD;
          -  There is confirmed laboratory diagnosis of HIV infection (positive ELISA HIV antibody&#xD;
             test confirmed by Western blot, p24 antigen assay, quantitative HIV-1 RNA assay, or&#xD;
             HIV culture).&#xD;
&#xD;
          -  The patient is at least 18 years of age.&#xD;
&#xD;
          -  ART-naïve, lopinavir/ritonavir susceptible on genotypic testing, CCR5-tropic virus on&#xD;
             Trofile testing (ESTA).&#xD;
&#xD;
          -  Negative pregnancy test within 72 hours prior to start of study for women of&#xD;
             childbearing potential.&#xD;
&#xD;
          -  Females of childbearing potential and males must utilize effective barrier&#xD;
             contraception.&#xD;
&#xD;
          -  HIV RNA greater than 1,000 copies per mL at entry.&#xD;
&#xD;
          -  Liver enzymes (AST, ALT) &lt; 3 times the upper limit of normal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are pregnant or breast-feeding.&#xD;
&#xD;
          -  Active alcohol or substance abuse sufficient, in the Investigator's opinion that makes&#xD;
             compliance to the study protocol unlikely.&#xD;
&#xD;
          -  Suspected or active HIV-related opportunistic infection or condition requiring acute&#xD;
             therapy within 30 days of entry into the trial.&#xD;
&#xD;
          -  Patients on therapy for hepatitis B.&#xD;
&#xD;
          -  Patients with hepatitis B surface antigen, or any evidence of active hepatitis B such&#xD;
             as positive hepatitis B DNA and/or presence of hepatitis e antigen or e antibody.&#xD;
&#xD;
          -  Acute hepatitis B or C within 60 days of entry.&#xD;
&#xD;
          -  Patients harboring preexistent co-receptor CXCR4 tropic or dual-or mixed-tropic HIV.&#xD;
&#xD;
          -  Patients harboring HIV resistant to lopinavir/ritonavir on genotypic testing.&#xD;
&#xD;
          -  The presence of decompensated heart failure, myocardial infarction within 1 year,&#xD;
             bypass surgery, severe vascular disease, or active hepatobiliary disease.&#xD;
&#xD;
          -  Concomitant use of rifampin, ergot derivatives (i.e. dihydroergotamine, ergotamine),&#xD;
             cisapride, lovastatin, simvastatin, triazolam, orally administered midazolam,&#xD;
             carbamazepine, phenytoin, St. John's wort, ketoconazole, itraconazole, clarithromycin,&#xD;
             telithromycin, amiodarone, bepridil, flecainide, propafenone, quinidine, voriconazole&#xD;
             or nefazodone.&#xD;
&#xD;
          -  Patients with concomitant diagnosis of malignancy or cancer other than basal cell&#xD;
             carcinoma within the past 5 years.&#xD;
&#xD;
          -  Concomitant use of investigational agents including the use of any investigational&#xD;
             vaccines.&#xD;
&#xD;
          -  Any other clinical conditions or prior therapy that, in the opinion of the&#xD;
             investigator, would make the patient unsuitable for study, or unable to comply with&#xD;
             the dosing requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary van den Berg-Wolf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Temple General Internal Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 12, 2010</study_first_submitted>
  <study_first_submitted_qc>February 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2010</study_first_posted>
  <results_first_submitted>September 9, 2020</results_first_submitted>
  <results_first_submitted_qc>October 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2020</results_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Protease Inhibitor</keyword>
  <keyword>CCR5 Co-receptor Antagonist</keyword>
  <keyword>treatment naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Open Label Single Arm</title>
          <description>Drug: lopinavir/ritonavir plus maraviroc&#xD;
lopinavir/ritonavir plus maraviroc: Lopinavir/ritonavir 400 mg/100 mg two tablets twice daily with Maraviroc 150 mg one tablet twice daily will be administered for 48 weeks to participants meeting entry criteria.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Open Label Single Arm</title>
          <description>Drug: lopinavir/ritonavir plus maraviroc&#xD;
lopinavir/ritonavir plus maraviroc: Lopinavir/ritonavir 400 mg/100 mg two tablets twice daily with Maraviroc 150 mg one tablet twice daily will be administered for 48 weeks to participants meeting entry criteria.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" lower_limit="29" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assess Proportion of Participants With HIV RNA Levels &lt;50 and &lt; 400 Copies/mL.</title>
        <time_frame>week 48</time_frame>
        <population>Subject terminated study prior to week 48</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Single Arm</title>
            <description>Drug: lopinavir/ritonavir plus maraviroc&#xD;
lopinavir/ritonavir plus maraviroc: Lopinavir/ritonavir 400 mg/100 mg two tablets twice daily with Maraviroc 150 mg one tablet twice daily will be administered for 48 weeks to participants meeting entry criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Proportion of Participants With HIV RNA Levels &lt;50 and &lt; 400 Copies/mL.</title>
          <population>Subject terminated study prior to week 48</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HIV RNA &lt; 50 and &lt;400 Copies/ml.</title>
        <time_frame>week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label Single Arm</title>
            <description>Drug: lopinavir/ritonavir plus maraviroc&#xD;
lopinavir/ritonavir plus maraviroc: Lopinavir/ritonavir 400 mg/100 mg two tablets twice daily with Maraviroc 150 mg one tablet twice daily will be administered for 48 weeks to participants meeting entry criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HIV RNA &lt; 50 and &lt;400 Copies/ml.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess the Proportion of Participants at Study Termination With VL &lt; 50 Copies/ml.</title>
        <time_frame>week 48</time_frame>
        <population>Subject terminated study prior to week 48</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Single Arm</title>
            <description>Drug: lopinavir/ritonavir plus maraviroc&#xD;
lopinavir/ritonavir plus maraviroc: Lopinavir/ritonavir 400 mg/100 mg two tablets twice daily with Maraviroc 150 mg one tablet twice daily will be administered for 48 weeks to participants meeting entry criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Assess the Proportion of Participants at Study Termination With VL &lt; 50 Copies/ml.</title>
          <population>Subject terminated study prior to week 48</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine the Time to Viral Suppression (VL &lt; 50 Copies/ml).</title>
        <time_frame>48 weeks</time_frame>
        <population>Subject terminated study prior to week 48</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Single Arm</title>
            <description>Drug: lopinavir/ritonavir plus maraviroc&#xD;
lopinavir/ritonavir plus maraviroc: Lopinavir/ritonavir 400 mg/100 mg two tablets twice daily with Maraviroc 150 mg one tablet twice daily will be administered for 48 weeks to participants meeting entry criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Determine the Time to Viral Suppression (VL &lt; 50 Copies/ml).</title>
          <population>Subject terminated study prior to week 48</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine the Median Change in VL From Baseline to Week 24, to Week 48 and to Study Termination.</title>
        <time_frame>week 24, week 48</time_frame>
        <population>Analysis was not performed as only one subject was enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Single Arm</title>
            <description>Drug: lopinavir/ritonavir plus maraviroc&#xD;
lopinavir/ritonavir plus maraviroc: Lopinavir/ritonavir 400 mg/100 mg two tablets twice daily with Maraviroc 150 mg one tablet twice daily will be administered for 48 weeks to participants meeting entry criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Determine the Median Change in VL From Baseline to Week 24, to Week 48 and to Study Termination.</title>
          <population>Analysis was not performed as only one subject was enrolled</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess the Changes in CD4+ T Cell Count.</title>
        <time_frame>week 24, 48</time_frame>
        <population>Analysis was not performed because only 1 subject was enrolled and terminated study prior to week 48</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Single Arm</title>
            <description>Drug: lopinavir/ritonavir plus maraviroc&#xD;
lopinavir/ritonavir plus maraviroc: Lopinavir/ritonavir 400 mg/100 mg two tablets twice daily with Maraviroc 150 mg one tablet twice daily will be administered for 48 weeks to participants meeting entry criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Assess the Changes in CD4+ T Cell Count.</title>
          <population>Analysis was not performed because only 1 subject was enrolled and terminated study prior to week 48</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess Development of HIV Resistance Mutations and in HIV Co-receptor Tropism Changes in Participants Who Develop Virologic Rebound.</title>
        <time_frame>week 48</time_frame>
        <population>Subject terminated study prior to week 48</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Single Arm</title>
            <description>Drug: lopinavir/ritonavir plus maraviroc&#xD;
lopinavir/ritonavir plus maraviroc: Lopinavir/ritonavir 400 mg/100 mg two tablets twice daily with Maraviroc 150 mg one tablet twice daily will be administered for 48 weeks to participants meeting entry criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Development of HIV Resistance Mutations and in HIV Co-receptor Tropism Changes in Participants Who Develop Virologic Rebound.</title>
          <population>Subject terminated study prior to week 48</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Open Label Single Arm</title>
          <description>Drug: lopinavir/ritonavir plus maraviroc&#xD;
lopinavir/ritonavir plus maraviroc: Lopinavir/ritonavir 400 mg/100 mg two tablets twice daily with Maraviroc 150 mg one tablet twice daily will be administered for 48 weeks to participants meeting entry criteria.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lisa Landsberg</name_or_title>
      <organization>Lewis Katz School of Medicine at Temple University</organization>
      <phone>12157077303</phone>
      <email>lisa.landsberg@temple.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

